GGrantIndex
← Search

Analytical Pharmacology

$90,582P30FY2017CANIH

Beckman Research Institute/City Of Hope, Duarte CA

Investigators

Linked publications, trials & patents

Trial NCT07664670Trial NCT07664579Trial NCT07650656Trial NCT07628894Trial NCT07619599Trial NCT07612085Trial NCT07611370Trial NCT07608627Trial NCT07608458Trial NCT07608445Trial NCT07595874Trial NCT07590583Trial NCT07583810Trial NCT07583303Trial NCT07582172Trial NCT07582159Trial NCT07578077Trial NCT07578025Trial NCT07544992Trial NCT07365306Trial NCT07363408Trial NCT07293403Trial NCT07288034Trial NCT07278856Trial NCT07275216Trial NCT07271355Trial NCT07235501Trial NCT07226544Trial NCT07226102Trial NCT07225855Trial NCT07225738Trial NCT07220447Trial NCT07219147Trial NCT07218913Trial NCT07218718Trial NCT07218692Trial NCT07218510Trial NCT07210086Trial NCT07202247Trial NCT07184294Trial NCT07136493Trial NCT07133997Trial NCT07128680Trial NCT07126301Trial NCT07125729Trial NCT07042438Trial NCT07040982Trial NCT07037004Trial NCT07025564Trial NCT07025538Trial NCT07020533Trial NCT07003100Trial NCT06996119Trial NCT06985784Trial NCT06954831Trial NCT06922604Trial NCT06918431Trial NCT06910761Trial NCT06860815Trial NCT06859008Trial NCT06834126Trial NCT06815029Trial NCT06815003Trial NCT06780787Trial NCT06763341Trial NCT06763328Trial NCT06735690Trial NCT06735664Trial NCT06731894Trial NCT06675136Trial NCT06675123Trial NCT06672224Trial NCT06626256Trial NCT06625619Trial NCT06581211Trial NCT06580015Trial NCT06575725Trial NCT06575686Trial NCT06575296Trial NCT06572631Trial NCT06572618Trial NCT06572605Trial NCT06549478Trial NCT06543381Trial NCT06538389Trial NCT06500377Trial NCT06498973Trial NCT06454409Trial NCT06454383Trial NCT06453044Trial NCT06447987Trial NCT06440850Trial NCT06408220Trial NCT06399419Trial NCT06328621Trial NCT06287944Trial NCT06260033Trial NCT06249282Trial NCT06196008Trial NCT06195891

Abstract

PROJECT SUMMARY (See instructions): The Analytical Pharmacology Core Facility (APCF) encourages and facilitates collaborative research among COHCCC basic scientists and clinicians by providing a wide range of analytical and consultative services. APCF assists with the design and conduct of pharmacokinetic studies for clinical and preclinical investigations. Primary services provided are: 1) quantitative assay development and sample analysis (LCMS/ MS, GC/MS, AAS, and HPLC) of drugs, biomarkers, and related compounds, and 2) study design and expert analysis of pharmacokinetic and metabolite data. APCF is located in the Shapiro Building and all of the major analytical equipment is consolidated into a contiguous suite of rooms. The most heavily utilized major equipment within the core are the 3 LC-MS/MS instruments, including a Micromass Quattro Ultima triple quad, a Waters Quattro Premier XE triple quad, and an AB Sciex QTRAP 5500. Each of these instruments includes different HPLC components with unique features that provide greater flexibility, and each of the systems provides state-of-the-art selectivity and sensitivity for analytes in complex biological matrices. Instrument control and data acquisition for the Micromass and Waters systems are coordinated through separate MassLynx-NT Workstations running MassLynx and QuanLynx software. MetaboLynx software is also available for the Quattro Premier XE to aid in metabolite identification. Instrument control and data analysis for the QTRAP 5500 is performed on a dedicated workstation running Analyst software. Additional core equipment includes: a Shimadzu Model QP-5000 El gas chromatograph/mass spectrometer, interfaced directly to a dedicated PC running CLASS-5000 software; a Perkin Elmer AAnalyst 300 AAS with an HGA 800 graphite furnace for determination of metals and metal containing compounds; and three complete HPLC systems consisting of six solvent delivery modules (4 Shimadzu LC-IOA's, 2 Shimadzu LClOAD's). HPLC detection capabilities cover a wide range of currently available methods, including UV/Vis (Shimadzu SPD-10AV), fluorescence (Shimadzu RF-10A), electrochemical (ESA models 51 OOA and 5200A), and photodiode array (Waters Acquity PDA) detection systems. Between July 1, 2010 and June 30, 2011, a total of 13 analytical methods were developed or re-initiated, 2657 samples analyzed, and 907 clinical samples processed during the reporting period.

View original record on NIH RePORTER →